Ketamine Harm Reduction

Ketamine prescribed off label is a legal possibility for some use cases. Your medical provider and pharmacist will discuss the various indications and risks involved. Talk to your independent medical provider to see if you might be a candidate for this medicine in conjunction with psychotherapy

Ketamine Harm Reduction
Ketamine Harm Reduction

Safety and efficacy of ketamine for a number of indications have been studied since 1962, however ketamine is only FDA-approved as a dissociative anesthetic and sedative. The FDA approved half of the molecule of ketamine, esketamine, for Treatment Resistant Depression with and without suicidality.

Ketamine prescribed off label is a legal possibility for some use cases, and your medical provider and pharmacist will discuss the various indications and risks involved in various doses and routes of administration.

Talk to your independent medical provider to see if you might be a candidate for this medicine in conjunction with cognitive behavioral therapy. Your medical provider will discuss other treatment approaches and options as indicated by ongoing, rigorous study.

Ketamine Hydrochloride Monograph for Professionals - Drugs.com
Ketamine Hydrochloride reference guide for safe and effective use from the American Society of Health-System Pharmacists (AHFS DI).

Ketamine | National Institute on Drug Abuse
Learn more about the dissociative drug ketamine.
Cracking the Ketamine Code
NIMH supported science and NIMH researchers helped pave the way for the development of ketamine—a groundbreaking treatment that has improved the lives of those who are impacted by treatment-resistant depression.
Spravato Side Effects: Common, Severe, Long Term
Learn about the side effects of Spravato (esketamine), from common to rare, for consumers and healthcare professionals.

On Ketamine Bladder Risks

(Formatting edits incoming)

Urothelial toxicity of esketamine in the treatment of depression - Psychopharmacology
Rationale Ketamine is the first widely used substance with rapid-onset antidepressant action. However, there are uncertainties regarding its potential urothelial toxicity, particularly after repeated application. In the context of rising recreational ketamine use, severe side effects affecting the human urinary tract have been reported. It is assumed that ketamine interacts with bladder urothelial cells and induces apoptosis. Objectives This study aimed to assess whether single or repeated doses of esketamine used in an antidepressant indication are associated with urinary toxicity. Methods We included male and female inpatients with a current episode of depression and a diagnosis of recurrent depressive disorder, bipolar disorder or schizoaffective disorder according to ICD-10 criteria (n = 25). The esketamine treatment schedule involved a maximum of 3× weekly dosing at 0.25–0.5 mg/kg i.v. or s.c. The primary outcome was the change in urine toxicity markers (leukocytes, erythrocytes, protein and free haemoglobin). Description of demographic, clinical and laboratory data was conducted using means, standard deviations, frequencies and percentages. Changes in urinary toxicity markers over time were evaluated using linear mixed models with gender as a covariate. Results The participants received an average of 11.4 (SD 8) esketamine treatments, and an average number of 11.2 (SD 8) urine samples were analysed over the course of treatment. Neither urinary leukocyte concentration (F(20; 3.0) = 3.1; p = 0.2) nor erythrocyte concentration (F(20;2.2) = 4.1; p = 0.2) showed a significant trend towards increase during the course of esketamine treatment. Similarly, free haemoglobin and protein concentrations, which were analysed descriptively, did not display a rise during treatment. There was a significant improvement in depression ratings after esketamine treatment (p < 0.001). Conclusions This study is, to the best of our knowledge, the first to focus on urothelial toxicity of esketamine used in antidepressant indication and dose. The results indicate that the use of single or repeated doses of esketamine is unlikely to cause urothelial toxicity. The results are in need of confirmation as sample size was small.



"The results indicate that the use of single or repeated doses of esketamine at 0.25–0.5 mg/kg is unlikely to cause urothelial toxicity."

https://www.psychiatrist.com/jcp/depression/oral-ketamine-for-depression-practical-considerations/



"There were no cases of bladder toxicity."

https://link.springer.com/article/10.1007/s00213-020-05611-y#Sec11

https://www.researchgate.net/profile/Luke-Jelen/publication/349251889_Ketamine_for_depression/links/60560e33458515e8345ccc0c/Ketamine-for-depression.pdf



"It should be noted that recreational ketamine consumption tends to be several orders of magnitude higher (one survey reported 34% of users reported use of 1 g or more in a typical session(Winstock et al., 2012)) than the doses prescribed in the clinical setting for depression. Although adverse effects of long-term ketamine use on the bladder would not necessarily be expected with the therapeutic dosing and frequency used in the treatment of depression, the lack of assessment of urinary symptoms has been another limitation in RCTs of ketamine (Short et al., 2018)."

https://citeseerx.ist.psu.edu/viewdoc/download?doi=10.1.1.1022.6283&rep=rep1&type=pdf



"Additionally, concerns have been raised about the possible incidence of bladder toxicity with repeated ketamine use (Middela, 2011). Only future clinical research can establish whether maintenance ketamine infusions represent a safe and effective option for initial ketamine responders."

https://www.tandfonline.com/doi/pdf/10.1080/00952990.2020.1769118

"Scientific data show that, in a clinical setting, the applied doses of ketamine are well-tolerated by humans and its negative effects are manageable. These effects seem to be dose and frequency-related, which is strongly supported by the scientific literature and by the analyzed threads, where the adverse effects of ketamine were mentioned as mild and manageable."

https://core.ac.uk/download/pdf/161939325.pdf



"The most serious of these side effects is ketamine-induced ulcerative cystitis or ‘ketamine bladder’. This is a recently identified condition characterised by extremely painful and frequent urination that seems to have severe and potentially long lasting impacts on the patient. However, drug users who take ketamine less than daily have not reported, and show no evidence of ‘ketamine bladder’.

Self Management and Recovery Training (SMART)

Learn About SMART Recovery - SMART Recovery
Learn about SMART Recovery with these videos and slideshows. Learn what to expect at meetings, how SMART Recovery works, and get started with the ABC and CBA tools from the SMART Recovery Toolbox. Check out the SMART Recovery ABOUT video (below). What to Expect at a SMART Recovery Meeting Lorie…

SMART Recovery was established in 1994 to meet the increasing demand of those seeking a secular and evidence-informed alternative to the widespread 12-Step addiction recovery program based on cognitive behavioral therapy. SMART Recovery also trains facilitators and mental health providers and allied fields.

SMART Recovery picks up with at home and community resources where cognitive behavioral therapy leaves off, especially for people dealing with problematic behaviors like substance dependence. Building this resource into the treatment plan offers another safeguard against the misuse of medicines, or other compulsive types of cravings and behaviors that end with personal and/or social harm. They offer great tools, regular meetings around the world and online.

66 years ago, the founder of Alcoholics Anonymous tried LSD — and ignited a controversy still raging today
Bill Wilson, the founder of Alcoholics Anonymous, was ostracized for saying LSD could benefit alcoholics. Modern science is proving him right.